Werewolf Therapeutics, Inc. (HOWL)
| Previous close | 5.1700 |
| Open | 4.7300 |
| Bid | 3.9200 x 200 |
| Ask | 4.0500 x 200 |
| Day's range | 3.8900 - 4.7300 |
| 52-week range | 1.5740 - 8.1940 |
| Volume | |
| Avg. volume | 175,468 |
| Market cap | 172.952M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.50 |
GlobeNewswireWerewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response - - Monotherapy recommended dose for expansion selected and expansion arms open for enrollment - - Preliminary data on WTX-124 administered to patients in combination with pembrolizumab showed that the combination was ge
- GlobeNewswire
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside ch
- GlobeNewswire
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers - - Preliminary data on WTX-124 administered in combination with pembrolizumab show similar tolerability to WTX-124 monotherapy - - Additional details and data post abstract cut-off date to be presented at ASCO - - Company to host webcast to review these data on Monday, June 3, 2024, at 8:00 am ET - WAT
